GlaxoSmithKline, Vir target emergency authorization for intramuscular COVID-19 antibody drug with new trial win

GlaxoSmithKline and Vir Biotechnology’s COVID-19 antibody drug sotrovimab already bears an FDA emergency use authorization as an infusion. Now, the pair hopes to win the same status for an intramuscular formulation.